http://oxfordpharmascience.com/


Oxford Pharmascience is a drug development company that re-develops approved drugs to make them better, safer and easier to take.

Oxford Pharmascience is using its proprietary oral drug delivery technologies to develop improved formulations of non-steroidal anti-inflammatory drugs (NSAIDs) and statins for global markets.

The Company's risk-diversified pipeline of prescription and OTC medicines is focused on cardiovascular disease and pain relief indications. Since the products incorporate previously approved drugs, this reduces risk and results in a simplified drug development regulatory pathway allowing less expensive development programs and faster access to market.

The Company has also commercialized calcium/vitamin D chews that taste better and dissolve faster than currently available regular formats. These products are now marketed in the UK, Middle East and Brazil.

Oxford Pharmascience is located in the UK and is led by a highly experienced management team that directs and manages the outsourcing of its development; pre-clinical and clinical programs; and manufacturing to a trusted network of partners and suppliers.

The Company commercializes its portfolio of product opportunities through out-licensing to leading pharmaceutical companies worldwide. Currently the Company has partnerships with Aché Laboratories and Bayer.

Oxford Pharmascience (LON:OXP) was established by a team of entrepreneurs in 2008 and is a publicly listed company on London's Alternative Investment Market (AIM), with a strong blue chip investor base.

UPDATE: Oxford Pharmascience eyes huge opportunity in statins with UCL deal


http://www.proactiveinvestors.co.uk/companies/news/48053/update-oxford-pharmascience-eyes-huge-opportunity-in-statins-with-ucl-deal-48053.html


Oxford Pharma snaps up delivery know-how for heart disease drugs

http://www.proactiveinvestors.co.uk/companies/news/48037/oxford-pharma-snaps-up-delivery-know-how-for-heart-disease-drugs--48037.html

Took a position mid afternoon at 1.27p. Lets see how this one goes.

Oxford Pharmascience publishes its interim results for the six months to 30 June 2012



http://www.moneyam.com/action/news/showArticle?id=4445829

Revenues leap at Oxford Pharmascience
By Michael Millar

Mon 17 Sep 2012

OXP - Oxford Pharmascience Group

Latest Prices
Name Price %
Oxford Pharmascience Group 1.40p +1.82%

Pharmaceuticals & Biotechnology 9,741 +0.54%

LONDON (SHARECAST) - Oxford Pharmascience saw revenues jump in the first half after it signed a sales deal with one of Brazil's largest pharmaceutical companies.

Revenues came in at £341,000, up from £20,000 the year before, with sales to Brazil's Aché making up the lions share.

The pharmaceutical technology company cut its pre-tax loss to £399,000, from £501,000 in the first half of 2011, with loss per share coming in at 0.07p.

Chairman David Norwood said 2011 was a breakthrough year for the company, having changed its focus to the higher value pharmaceutical market.

"The commencement of sales to Aché, one of Brazil's largest pharmaceutical companies and the launch of its OXP zero taste masking technology left [the company] well placed going into this year," he said

Oxford Pharma points to progress in busy first half
17 September 2012 | 10:07am
StockMarketWire.com - Oxford Pharmascience reports that revenues from its OXPchew™ technology continue to grow with strong sales from Aché and earlier than expected commencement of revenues to the Far East.

Importantly the company signed its first licensing deal with a major global pharmaceutical company, Bayer. This demonstrates our ability to do commercial deals with the 'big boys' and bodes exceedingly well if this is repeated for the OXPzero™ and OXPtarget™ technologies.

Co-development work has begun with Hermes Pharma for a range of ibuprofen direct to mouth granules using OXPzero™. This will result in clinical studies later this year to demonstrate the bio-equivalence of our OXPzero™ ibuprofen salt, a major step towards securing the first licensed medicine using the technology.

Repeating the success of the OXPchew™ business with OXPzero™ by first commercialising a product and then extending this to deals with other highly reputable pharmaceutical companies in ibuprofen alone will take the company a long way forward.



At 10:07am: (LON:OXP) share price was +0.03p at 1.4p

Good recovery, up 6% with good buying

scale up of taste masked ibuprofen for trials
RNS
RNS Number : 4951N
Oxford Pharmascience Group PLC
01 October 2012



Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Oxford Pharmascience announces successful scale up of taste masked ibuprofen for clinical trials

Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to reposition medicines, today announces it has completed successful first stage commercial scale up work for its OXPzero™ taste masked ibuprofen.

Over the last few months the Company has been working with a contract manufacturing partner to produce the taste masked ibuprofen in a batch that is both scalable and suitable for product registration.

The Company will now progress to undertake a clinical trial with their co-development partner Hermes Pharma to demonstrate the bio-equivalence of their taste masked ibuprofen, results of which are expected in the first quarter of 2013.

Nigel Theobald, Chief Executive, Oxford Pharmascience Group Plc, commented:

"This is a significant step forward in the commercialisation of our OXPzero™ technology. We now have a robust scalable production process and can make GMP grade material which is essential for use in human studies.

Having already demonstrated commercial success for our OXPchew™ technology, with sales growing in Brazil through Aché and partners like Bayer signed, this milestone shows we are making excellent progress towards the commercialisation of our OXPzero™ taste masking technology.

The global ibuprofen market alone is worth $2.7bn and dominated by tablet formulations due to the bitterness and burning sensation of pure ibuprofen. OXPzero allows major brands to formulate high dose non tablet products, without any burn. This milestone is another positive step forward in our confidence that OXPzero will become the leading taste masking technology for all nonsteroidal anti-inflammatory drugs."

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

Hybridan LLP (Broker)

Claire Noyce / Deepak Reddy +44 20 7947 4350

ZAI Corporate Finance (Nominated Adviser)

John Depasquale/ John Treacy +44 20 7060 2220

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc develops advanced yet practical pharmaceutical technologies to enable reformulation that adds value to off patent and soon to be off patent drugs. The Company does not manufacture or sell its own pharmaceutical products but instead seeks to license its technologies to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios. These partners use our technologies to reposition their products helping them sustain market share and profitability by delivering improved health outcomes and/or clinical profiles via reformulated versions of the same API (active pharmaceutical ingredient).

Oxford Pharmascience Group Plc develops platform technologies that have application across multiple drug categories and can be leveraged across a broad range of reformulation problems. This business model allows us to provide solutions across the industry and fund the ongoing development of cutting edge technologies to better serve the needs of our partners. The partner companies who adopt our technology pay an up-front license fee followed by development milestone payments and then royalties on finished products sold using the technology. OXP invests the upfront licence fee to optimise product development and to ensure seamless technology transfer to the pharmaceutical partner

Late buying today, pushed the sp up 7%

Oxford Pharmascience raises £2mln, eyes more contracts
7:38 am by Philip WhiterowCommercial discussions are also ongoing in relation to additional OXPchew and OXPzero based products.

Oxford Pharmascience (LON:OXP) is to raise £2 million through a share placing to fund further development of its soft chew and taste-masking platforms, and for new applications.

The firm has three core technology platforms: the soft chew technology, OXPchew; taste-masking platform OXPzero; and OXPtarget, a controlled-release technology.

This year it says it has made progress building commercial opportunities for its OXPchew technology and co-developing a novel ibuprofen product with Hermes Pharma, which it expects to continue to deliver a mixture of sales and royalties in connection with these products.

Today, it said commercial discussions are also ongoing in relation to additional OXPchew and OXPzero based products.

“Although neither the timing nor the scale of any commercial developments can be certain, the board reasonably expects near term progress to be made.

“Further announcements are likely to be made before the year end and one or more contracts possibly could materialise before completion of the placing; further announcements will be made as appropriate.”

The £2mln will be raised through a placing at 1.3p, mainly to institutions, with N+1 Singer the broker to the placing

Nigel Theobald, chief executive officer (CEO), said: "The company has made strong progress over the past eighteen months in developing and commercialising its innovative technology platforms.

The placing will put Oxford Pharmascience in a stronger position for continuing this effort, both in relation to its existing soft chew and taste-masking platforms and with new applications such as its colonic delivery statin products, which the directors believe will build material shareholder value by developing sustainable income streams over the longer term."

OXPchew Feasibility and Option Agreement
RNS
RNS Number : 0340S
Oxford Pharmascience Group PLC
27 November 2012

Oxford Pharmascience Group plc

("Oxford Pharmascience")



Oxford Pharmascience announces OXPchew Feasibility and Option agreement with Major Healthcare Company

Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutical technologies to reformulate medicines, today announces it has signed a feasibility and option agreement with a major healthcare company ("The Company") to develop a dietary supplement product using OXP's chew technology for The Company.

Under the terms of the agreement, The Company has engaged Oxford Pharmascience to develop prototype products using its OXPchew technology and received an option to negotiate an exclusive licensing agreement to sell those products under its main multivitamin brand.

Nigel Theobald, Chief Executive, Oxford Pharmascience Group Plc, commented:

"This deal represents further progress in the development of our OXPchew business, which is now providing strong and growing revenue. We are making great progress in the £1bn global calcium market and this agreement provides the potential opportunity for us to enter the even larger £4bn+ multivitamin market, with a leading global Multivitamin brand.

We continue to show that our technologies once commercialised are capable of attracting some of the best healthcare companies worldwide as partners".

up 10%

OXPZero Feasibility and Option Agreement
RNS
RNS Number : 5004S
Oxford Pharmascience Group PLC
03 December 2012

Oxford Pharmascience Group plc ("Oxford Pharmascience")

OXPzeroTM Feasibility and Option agreement with Major Healthcare Company





Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to reformulate medicines, today announces it has signed a feasibility and option agreement with a major healthcare company ("The Company"), to develop a range of undisclosed 'on the go' taste masked products.



Under the terms of the agreement, The Company has engaged Oxford Pharmascience to develop prototypes using its OXPzeroTM technology for a range of non tablet products that can be taken 'on the go' for inclusion in market research to determine the best products. Upon successful completion of the feasibility program, The Company will have an option for an exclusive worldwide license to sell the products under one of its main brands.





Nigel Theobald, Chief Executive, Oxford Pharmascience Group Plc, commented:



"This deal represents another major milestone in the commercialisation of our OXPzero technology."



Working with a leading global brand shows both credibility and potential. This is a very exciting deal for the future of our taste masking technology ".

For further information:

Oxford Pharmascience signs deal with ‘major healthcare company’ for taste-masking products
8:46 am by Jamie NimmoOXPzero allows acidic and anionic drugs to be administered orally without bad taste or irritation in non-tablet form and without affecting the drug's release in the body







Oxford Pharmascience (LON:OXP) has signed a feasibility and option agreement with a “major healthcare company” to develop a range of ‘on the go’ taste-masking products.

The pharmaceutical technology firm will develop prototypes using Oxford’s OXPzero platform to determine the best non-tablet products.

The company did not reveal the name of the partner firm but referred to it as a “major healthcare company”.

OXPzero allows acidic and anionic drugs to be administered orally without bad taste or irritation in non-tablet form. At the same time, however, it does not affect the drug’s release in the body.

“This deal represents another major milestone in the commercialisation of our OXPzero technology,” said Nigel Theobald, Oxford’s chief executive.

“Working with a leading global brand shows both credibility and potential. This is a very exciting deal for the future of our taste masking technology.”

Once the feasibility programme has been successfully completed, the healthcare company will have an option for an exclusive worldwide licence to sell the products under one of its main brands, Oxford said.

The news comes just a week after Oxford signed a similar deal with a “leading multivitamin brand” to develop a dietary supplement using the company's OXPchew technology.

Shares rose 0.15p or 8.8% to 1.85p.

Result of Meeting - Approval of Placing
RNS
RNS Number : 3489T
Oxford Pharmascience Group PLC
12 December 2012

Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company")

Result of General Meeting - Approval of Placing

Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to reformulate medicines, announces that at its General Meeting held this morning at 10 a.m., the resolution was duly passed.

Accordingly, the conditional placing announced on 26 November, 2012 is now unconditional in all respects save for admission of the 153,846,154 new ordinary shares of 0.1 pence each. Admission is expected to take place at 8 a.m. on Thursday 13 December, 2012.

Following Admission, the Company will have 730,869,952 Ordinary Shares in issue. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 730,869,952 and this figure may therefore be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

Nigel Theobald, CEO, commented:

"The Company looks forward to applying the proceeds from the placing to commercialising further its existing soft chew and taste-masking platforms, and to developing new applications including the colonic delivery statin products.

Oxford Pharmascience recently confirmed a feasibility and option agreement with a major healthcare company for a multivitamin supplement using OXPchew technology, and a similar type of agreement with another major to develop a range of 'on the go' non-tablet, taste masked products using OXPzero. The Company can therefore look forward to ongoing positive newsflow as it builds further shareholder value from its reformulation platform and know-how."

N+1 Singer sees Oxford Pharmascience (LON:OXP) as an appealing investment case thanks to its diversified technology platforms, strong IP protection and generic drugs dossier ownership.

The broker, which has a target price of 13.41p, believes Oxford is well placed for growth with significant opportunities in the pipeline.

investors who participated in the company’s £2mln fund-raising in November at 1.3p a share are sitting on a pretty profit, with the shares currently trading at around 2.2p


Top 10 Emerging Technology Company in 2012
RNS
RNS Number : 0467U
Oxford Pharmascience Group PLC
20 December 2012

Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company")

Named as Top Emerging Technology Company in 2012

Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to reformulate medicines, has been featured in Lux Research's "Top Emerging Technology Companies in 2012".

Lux Research profiled 1,380 companies across 15 different emerging technology domains in 2012 and to conclude the year, selected the 10 most compelling companies they had profiled in 2012 across all its coverage areas, with Oxford Pharmascience making the top 10.



Nigel Theobald, CEO, commented:

"It is fantastic to be recognised in this way by such a respected research company as Lux.

We have invested in some exciting technologies for reformulating existing medicines and wholeheartedly agree that through our partnerships with major pharma companies we will indeed have some very compelling products to bring to market "

Moving up well

up 10.5%, Im a 100% upat 2.54p, in at 1.27p

Well done DreamCatcher!